Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in December 2025 and January 2026 as a material inducement to their employment.

GlobeNewsWire • Jan 20, 2026

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I.

GlobeNewsWire • Jan 5, 2026

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated's (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Benzinga • Dec 22, 2025

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Seeking Alpha • Dec 22, 2025

Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up

CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.

Zacks Investment Research • Dec 22, 2025

Cytokinetics: Small Label Differences With Big Commercial Stakes

Cytokinetics, Incorporated remains a Buy following FDA approval of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM). ORZO's label offers subtle practical advantages over CAMZYOS, notably flexible dosing, enhancing real-world usability. CYTK management targets >50% preference share and increased category penetration to mid-high 20% by the end of 2026, which implies gradual adoption and reliance on assistance programs.

Seeking Alpha • Dec 22, 2025

US FDA approves Cytokinetics' heart disease drug

The U.S. Food and Drug Administration has approved Cytokinetics' drug to treat a rare heart condition, the company said on Friday.

Reuters • Dec 19, 2025

Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms

Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.

Investors Business Daily • Dec 19, 2025

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500.

The Motley Fool • Dec 19, 2025